<DOC>
	<DOCNO>NCT01324492</DOCNO>
	<brief_summary>The present study design collect safety/tolerability data explore efficacy RAD001 advance pulmonary neuroendocrine tumor Chinese patient .</brief_summary>
	<brief_title>Safety Efficacy RAD001 Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm carcinoid tumor Newly diagnose advanced carcinoid tumor progress 1st line treatment eligible Patients either clinically apparent central nervous system metastases carcinomatous meningitis ( nonclinical symptom brain lesion eligible ) Received Cytotoxic chemotherapy , immunotherapy radiotherapy prior enrollment Patients concurrent malignancy , history prior malignancy within past three year , except basal cell squamous cell skin cancer , carcinoma situ cervix , treat early stage ( T1a ) prostate cancer treat early stage ( DCIS LCIS ) breast cancer Prior therapy RAD001 mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>phase Ib ,</keyword>
	<keyword>RAD001 ,</keyword>
	<keyword>advanced pulmonary neuroendocrine tumor</keyword>
</DOC>